[Special issue PRO] A demonstration of estimands and sensitivity analyses for time-to-deterioration of patient reported outcomes

References

• Anota, A., Z. Hamidou, S. Paget-Bailly, B. Chibaudel, C. Bascoul-Mollevi, P. Auquier, V. Westeel, F. Fiteni, C. Borg, and F. Bonnetain. 2015. Time to health-related quality of life score deterioration as a modality of longitudinal analysis for health-related quality of life studies in oncology: Do we need RECIST for quality of life to achieve standardization? Quality of Life Research 24 (1):5–18. doi:10.1007/s11136-013-0583-6.
   PubMed Web of Science ®Google Scholar
• Atkinson, A., M. G. Kenward, T. Clayton, and J. R. Carpenter. 2019. Reference‐based sensitivity analysis for time‐to‐event data. Pharmaceutical Statistics 18 (6):645–658. doi:10.1002/pst.1954.
   PubMed Web of Science ®Google Scholar
• Bonnetain, F., L. Dahan, E. Maillard, M. Ychou, E. Mitry, P. Hammel, J.-L. Legoux, P. Rougier, L. Bedenne, and J.-F. Seitz. 2010. Time until definitive quality of life score deterioration as a means of longitudinal analysis for treatment trials in patients with metastatic pancreatic adenocarcinoma. European Journal of Cancer 46 (15):2753–2762. doi:10.1016/j.ejca.2010.07.023.
   PubMed Web of Science ®Google Scholar
• Bonnetain, F., F. Fiteni, F. Efficace, and A. Anota. 2016. Statistical challenges in the analysis of health-related quality of life in cancer clinical trials. Journal of Clinical Oncology Official Journal of the American Society of Clinical Oncology 34 (16):1953–1956. doi:10.1200/JCO.2014.56.7974.
   PubMed Web of Science ®Google Scholar
• Bornkamp, B., K. Rufibach, J. Lin, Y. Liu, D. V. Mehrotra, S. Roychoudhury, H. Schmidli, Y. Shentu, and M. Wolbers. 2021. Principal stratum strategy: Potential role in drug development. Pharmaceutical Statistics 20 (4):737–751. doi:10.1002/pst.2104.
   PubMed Web of Science ®Google Scholar
• Carpenter, J. R., and M. G. Kenward. 2013. Multiple imputation and its application. John Wiley & Sons. https://www.wiley.com/en-us/Multiple+Imputation+and+its+Application±p-9780470740521.
   Google Scholar
• Carpenter, J. R., J. H. Roger, and M. G. Kenward. 2013b. Analysis of longitudinal trials with protocol deviation: A framework for relevant, accessible assumptions, and inference via multiple imputation. Journal of Biopharmaceutical Statistics 23 (6):1352–1371. doi:10.1080/10543406.2013.834911.
   PubMed Web of Science ®Google Scholar
• Charton, E., B. Cuer, F. Cottone, F. Efficace, C. Touraine, Z. Hamidou, F. Fiteni, F. Bonnetain, M.-C. Woronoff-Lemsi, and C. Bascoul-Mollevi. 2020. Time to deterioration in cancer randomized clinical trials for patient-reported outcomes data: A systematic review. Quality of Life Research 29 (4):867–878. doi:10.1007/s11136-019-02367-7.
   PubMed Web of Science ®Google Scholar
• Claggett, B., S. Pocock, L. J. Wei, M. A. Pfeffer, J. J. McMurray, and S. D. Solomon. 2018. Comparison of time-to-first event and recurrent-event methods in randomized clinical trials. Circulation 138 (6):570–577.
   PubMed Web of Science ®Google Scholar
• Coens, C., M. Pe, A. C. Dueck, J. Sloan, E. Basch, M. Calvert, A. Campbell, C. Cleeland, K. Cocks, and L. Collette. 2020. International standards for the analysis of quality-of-life and patient-reported outcome endpoints in cancer randomised controlled trials: Recommendations of the SISAQOL consortium. The Lancet Oncology 21 (2):e83–e96. doi:10.1016/S1470-2045(19)30790-9.
   PubMed Web of Science ®Google Scholar
• Cox, D. R. 1972. Regression models and life‐tables. Journal of the Royal Statistical Society: Series B (Methodological) 34 (2):187–202. doi:10.1111/j.2517-6161.1972.tb00899.x.
   Web of Science ®Google Scholar
• Europe, S. M. A. (2019). The patient voice at EMA. https://www.sma-europe.eu/news/the-patient-voice-at-ema
   Google Scholar
• Fiero, M. H., S. Huang, E. Oren, and M. L. Bell. 2016. Statistical analysis and handling of missing data in cluster randomized trials: A systematic review. Trials 17 (1):72. doi:10.1186/s13063-016-1201-z.
   PubMedGoogle Scholar
• Fiero, M. H., J. K. Roydhouse, V. Bhatnagar, T.-Y. Chen, B. L. King-Kallimanis, S. Tang, and P. G. Kluetz. 2022. Time to deterioration of symptoms or function using patient-reported outcomes in cancer trials. The Lancet Oncology 23 (5):e229–e234. doi:10.1016/S1470-2045(22)00021-3.
   PubMed Web of Science ®Google Scholar
• Floden, L., and M. L. Bell. 2019. Imputation strategies when a continuous outcome is to be dichotomized for responder analysis: A simulation study. BMC Medical Research Methodology 19 (1). doi:10.1186/s12874-019-0793-x.
   PubMedGoogle Scholar
• Grobler, A. C., K. J. Lee, A. Wong, D. C. Currow, and S. Braat. 2022. Handling missing data and drop out in hospice/palliative care trials through the estimand framework. Journal of Pain and Symptom Management 63 (4):e431–e439. doi:10.1016/j.jpainsymman.2021.12.022.
   PubMed Web of Science ®Google Scholar
• ICH. 2019 September 29. Addendum on Estimands and sensitivity analysis in clinical trials to the guideline on statistical principles for clinical trials E9(R1). Federal register FDA-20.
   Google Scholar
• Kaplan, E. L., and P. Meier. 1958. Nonparametric estimation from incomplete observations. Journal of the American Statistical Association 53 (282):457–481. doi:10.1080/01621459.1958.10501452.
   Web of Science ®Google Scholar
• King-Kallimanis, B. L., V. Bhatnagar, E. G. Horodniceanu, T.-Y. Chen, and P. G. Kluetz. 2022. Timing is everything: The importance of patient-reported outcome assessment frequency when characterizing symptomatic adverse events. Clinical Trials 19 (3):267–273. doi:10.1177/17407745221093935.
   PubMed Web of Science ®Google Scholar
• LaVange, L. M., and T. Permutt. 2016. A regulatory perspective on missing data in the aftermath of the NRC report. Statistics in Medicine 35 (17):2853–2864. doi:10.1002/sim.6840.
   PubMed Web of Science ®Google Scholar
• Lawrance, R., E. Degtyarev, P. Griffiths, P. Trask, H. Lau, D. D’Alessio, I. Griebsch, G. Wallenstein, K. Cocks, and K. Rufibach. 2020. What is an estimand & how does it relate to quantifying the effect of treatment on patient-reported quality of life outcomes in clinical trials? Journal of Patient-Reported Outcomes 4 (1). doi:10.1186/s41687-020-00218-5.
   PubMedGoogle Scholar
• Lipkovich, I., B. Ratitch, Y. Qu, X. Zhang, M. Shan, and C. Mallinckrodt. 2022. Using principal stratification in analysis of clinical trials. Statistics in Medicine 41 (19):3837–3877. doi:10.1002/sim.9439.
   PubMed Web of Science ®Google Scholar
• Little, R. J. A., and D. B. Rubin. 2002. Statistical analysis with missing data. Vol. 793. John Wiley & Sons. doi:10.1002/9781119013563.
   Google Scholar
• Mallinckrodt, C. H. (2013). Preventing and treating missing data in longitudinal clinical trials: A practical guide. https://books.google.com/books?hl=en&lr=&id=4VEH92XT-YoC&oi=fnd&pg=PR11&dq=Preventing+and+Treating+Missing+Data+in+Longitudinal+Clinical+Trials&ots=uxOmXa8aDt&sig=f0pXy4Fpjai5TwOU8ZtalYeVl3E
   Google Scholar
• Mallinckrodt, C. H., J. Bell, G. Liu, B. Ratitch, M. O’Kelly, I. Lipkovich, P. Singh, L. Xu, and G. Molenberghs. 2019. Aligning estimators with estimands in clinical trials: Putting the ICH E9(R1) guidelines into practice. Therapeutic Innovation & Regulatory Science 216847901983697:216847901983697. doi:10.1177/2168479019836979.
   Google Scholar
• Mantel, N. 1966. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemotherapy Reports Part 1 50 (3):163–170.
   PubMedGoogle Scholar
• Mehrotra, D. V., R. J. Hemmings, E. Russek-Cohen, and ICH E9/R1 Expert Working Group. 2016. Seeking harmony: Estimands and sensitivity analyses for confirmatory clinical trials. Clinical Trials (London, England) 13 (4):456–458. doi:10.1177/1740774516633115.
   PubMed Web of Science ®Google Scholar
• Panel on Handling Missing Data in Clinical Trials, & Committee on National Statistics Division of Behavioral and Social Sciences and Education. 2010. The prevention and treatment of missing data in clinical trials panel on handling missing data in clinical trials. National Research. In The National Academy of Sciences. http://www.nap.edu/catalog.php?record_id=12955.
   Google Scholar
• Thanarajasingam, G., E. Basch, C. Mead-Harvey, A. V. Bennett, G. L. Mazza, G. Schwab, J. Roydhouse, L. J. Rogak, and A. C. Dueck. 2022. An exploratory analysis of the “was it worth it?” questionnaire as a novel metric to capture patient perceptions of cancer treatment. Value in Health 25 (7):1081–1086. doi:10.1016/j.jval.2021.11.1368.
   PubMed Web of Science ®Google Scholar
• US FDA. (2019). The voice of the patient: A series of reports from FDA’s patient-focused drug development initiative. https://www.fda.gov/industry/prescription-drug-user-fee-amendments/voice-patient-series-reports-fdas-patient-focused-drug-development-initiative.
   Google Scholar
• US FDA. (2021, June). Core patient-reported outcomes in cancer clinical trials. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/core-patient-reported-outcomes-cancer-clinical-trials.
   Google Scholar
• US FDA. (n.d.). FDA patient-focused drug development guidance series for enhancing the incorporation of the patient’s voice in medical product development and regulatory decision making. Accessed March 12, 2023. https://www.fda.gov/drugs/development-approval-process-drugs/fda-patient-focused-drug-development-guidance-series-enhancing-incorporation-patients-voice-medical.
   Google Scholar
• van Buuren, S. 2007. Multiple imputation of discrete and continuous data by fully conditional specification. Statistical Methods in Medical Research 16 (3):219–242. doi:10.1177/0962280206074463.
   PubMed Web of Science ®Google Scholar
• Walding, A., K. Skaltsa, M. Casamayor, and A. Rydén. 2022. Time to deterioration of patient-reported outcomes in non-small cell lung cancer: Exploring different definitions. Quality of Life Research 31 (8):2535–2543. doi:10.1007/s11136-022-03088-0.
   PubMed Web of Science ®Google Scholar